Alto Neuroscience/ANRO

$12.47

-2.73%
-
1D1W1MYTD1YMAX

About Alto Neuroscience

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.

Ticker

ANRO

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Amit Etkin

Employees

63

Headquarters

Los altos, United States

ANRO Metrics

BasicAdvanced
$372M
Market cap
-
P/E ratio
-$1.42
EPS
-
Beta
-
Dividend rate
$372M
$24.00
$12.78
180K
15.221
14.127
14.127
5.33
-31.02%

What the Analysts think about ANRO

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 3 analysts.
159.26% upside
High $33.00
Low $32.00
$12.47
Current price
$32.33
Average price target

ANRO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
-55.2%
Profit margin
0%
NaN%

ANRO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 64.5%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Actual
-$7.77
-$0.76
-
Expected
-$1.67
-$0.46
-$0.49
Surprise
364.16%
64.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Alto Neuroscience stock?

Alto Neuroscience (ANRO) has a market cap of $345M as of May 19, 2024.

What is the P/E ratio for Alto Neuroscience stock?

The price to earnings (P/E) ratio for Alto Neuroscience (ANRO) stock is 0 as of May 19, 2024.

Does Alto Neuroscience stock pay dividends?

No, Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders as of May 19, 2024.

When is the next Alto Neuroscience dividend payment date?

Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Alto Neuroscience?

Alto Neuroscience (ANRO) does not currently have a Beta indicator.

What is the Alto Neuroscience stock price target?

The target price for Alto Neuroscience (ANRO) stock is $32.33, which is 159.26% above the current price of $12.47. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Alto Neuroscience stock

Buy or sell Alto Neuroscience stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing